RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Pliant Therapeutics EBIT 2024

Pliant Therapeutics EBIT

-224.9 M USD

Pliant Therapeutics Dividend yield

Ticker

PLRX

ISIN

US7291391057

WKN

A2P4YV

In 2024, Pliant Therapeutics's EBIT was -224.9 M USD, a 22.13% increase from the -184.15 M USD EBIT recorded in the previous year.

The Pliant Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

Pliant Therapeutics Aktienanalyse

What does Pliant Therapeutics do?

Pliant Therapeutics Inc is a biopharmaceutical company located in South San Francisco, California. The company was founded in 2016 by a group of scientists specializing in the discovery of therapeutics for the treatment of fibrosis and cancer. The history of Pliant Therapeutics Inc begins with the discovery of proteins involved in the development of fibrosis. These proteins, known as integrins, play a key role in tissue repair and regeneration. However, when they are overactive, they can lead to an overproduction of connective tissue, resulting in fibrosis. Pliant Therapeutics Inc aims to develop innovative therapeutics for the treatment of fibrosis and cancer. The company utilizes an innovative business model based on the discovery and development of novel therapeutics targeting the regulation of integrins. The company specializes in various areas. One important focus is the research of therapeutics for the treatment of lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit the fibrosis process and improve lung function. Another focus of Pliant Therapeutics Inc is the development of therapeutics for the treatment of connective tissue disorders, such as scleroderma and systemic lupus erythematosus (SLE). The company has also launched a program for the development of therapeutics for the treatment of cancer. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit tumor growth and improve the effectiveness of cancer drugs. Pliant Therapeutics Inc has several products in the pipeline, including PT004 for the treatment of lung diseases and PT001 for the treatment of scleroderma. PT004 is an inhalable drug that aims to inhibit the fibrosis process in the lungs. It is currently in Phase 2 of clinical development and has the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) and severe asthma. PT001 is an orally administered drug that targets the treatment of scleroderma. The drug is currently in preclinical development and has the potential to inhibit the fibrosis process in various organs. Overall, Pliant Therapeutics Inc has the potential to play a leading role in the discovery and development of novel therapeutics for the treatment of fibrosis and cancer. The company is well-funded and has an experienced team of scientists and managers specializing in the development of innovative therapeutics. Pliant Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Pliant Therapeutics's EBIT

Pliant Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Pliant Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Pliant Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Pliant Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Pliant Therapeutics Stock

How much did Pliant Therapeutics achieve in EBIT for the current year?

In the current year, Pliant Therapeutics has achieved an EBIT of -224.9 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Pliant Therapeutics.

How has the EBIT of Pliant Therapeutics developed in recent years?

The EBIT of Pliant Therapeutics has increased by 22.13% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Pliant Therapeutics?

The EBIT of Pliant Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Pliant Therapeutics pay?

Over the past 12 months, Pliant Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pliant Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pliant Therapeutics?

The current dividend yield of Pliant Therapeutics is .

When does Pliant Therapeutics pay dividends?

Pliant Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pliant Therapeutics?

Pliant Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pliant Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pliant Therapeutics located?

Pliant Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pliant Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pliant Therapeutics from 5/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/29/2024.

When did Pliant Therapeutics pay the last dividend?

The last dividend was paid out on 5/29/2024.

What was the dividend of Pliant Therapeutics in the year 2023?

In the year 2023, Pliant Therapeutics distributed 0 USD as dividends.

In which currency does Pliant Therapeutics pay out the dividend?

The dividends of Pliant Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Pliant Therapeutics

Our stock analysis for Pliant Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pliant Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.